(Q37629722)

21 August 2017

1 reference

title

Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors (English)

1 reference

21 August 2017

Austin Duffy

1

1 reference

PubMed ID

19899001

21 August 2017

Shivaani Kummar

series ordinal

2

1 reference

21 August 2017

10 November 2009

1 reference

21 August 2017

1 reference

21 August 2017

4

1 reference

21 August 2017

267-273

1 reference

21 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-009-0125-x

21 August 2017

0 references

cites work

Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-009-0125-X

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-009-0125-X

MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-009-0125-X

Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-009-0125-X

Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation

21 January 2018

1 reference

12 December 2020

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

1 reference

12 December 2020

Genetic predictors of MEK dependence in non-small cell lung cancer

1 reference

12 December 2020

Mitogen-activated protein kinase pathways

1 reference

12 December 2020

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

12 December 2020

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines

1 reference

12 December 2020

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

12 December 2020

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

1 reference

12 December 2020

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

12 December 2020

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

1 reference

12 December 2020

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

12 December 2020

ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia.

1 reference

12 December 2020

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

12 December 2020

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

1 reference

12 December 2020

Sorafenib in advanced hepatocellular carcinoma

1 reference

12 December 2020

Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells

1 reference

12 December 2020

Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy

1 reference

12 December 2020

Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer

1 reference

12 December 2020

The transcriptional response to Raf activation is almost completely dependent on Mitogen-activated Protein Kinase Kinase activity and shows a major autocrine component

1 reference

12 December 2020

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

1 reference

12 December 2020

Phase II trials in journal of clinical oncology

1 reference

12 December 2020

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy

1 reference

12 December 2020

Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines

1 reference

12 December 2020

Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma.

1 reference

12 December 2020

A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal

1 reference

12 December 2020

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

12 December 2020

Signaling by dual specificity kinases

1 reference

12 December 2020

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

1 reference

12 December 2020

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

1 reference

12 December 2020

Analysis of the transcriptional program induced by Raf in epithelial cells

1 reference

12 December 2020

Advances in preclinical small molecules for the treatment of NSCLC.

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

A genome-wide survey of RAS transformation targets

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

12 December 2020

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

12 December 2020

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins

1 reference

12 December 2020

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

1 reference

12 December 2020

RAS oncogenes: the first 30 years.

1 reference

12 December 2020

10.1007/S11523-009-0125-X

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19899001